Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Parkinson's disease therapies Tasmar (tolcapone) and Sinemet CR (sustained-release carbidopa-levodopa) will be co-promoted for three years in the U.S. Roche's Tasmar, approved Jan. 29, is indicated for use as an adjunct to carbidopa and levodopa therapy. Over 500 Roche reps and a "few hundred" DuPont reps will promote the compounds. The co-promotion agreement provides additional support to DuPont's second top-selling Rx product line as the company forges an independent presence after the dissolution of the DuPont Merck joint venture. DuPont says the agreement with Roche will not affect the profit equalization formula of its license of the antihypertensives Cozaar/Hyzaar to Merck: the formula takes into account sales of the Sinemet line as well as Cozaar/Hyzaar sales and spending

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts